Physician profile
Ian Fecko
NPI 1861587297
$2,400.79
in general payments reported to CMS, 2019-2025
22 companies · $382 in 2025
The $382 reported for 2025 was more than what 90% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $222 · 2020: $156 · 2021: $415 · 2022: $343 · 2023: $409 · 2024: $473 · 2025: $382.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $349.38 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $296.33 | 2019-2025 | Bexsero, Pediarix, Penmenvy |
| Supernus Pharmaceuticals, INC. | $274.21 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $219.31 | 2022-2024 | Azstarys |
| Sanofi Pasteur INC. | $217.40 | 2019-2025 | |
| Pfizer INC. | $208.25 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $172.31 | 2019-2025 | Vaxneuvance, Gardasil 9, Gardasil |
| Sanofi-Aventis U.S. LLC | $112.69 | 2023-2025 | |
| Seqirus USA INC | $78.41 | 2022-2024 | Flucelvax, Flucelvax Quadrivalent |
| Astrazeneca Pharmaceuticals Lp | $74.90 | 2021-2023 | Flumist Quadrivalent |
| Tris Pharma INC | $71.28 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.41 | 2021 | |
| Sobi, INC | $44.04 | 2019-2022 | |
| Novo Nordisk INC | $43.34 | 2021-2024 | Wegovy |
| Shire North American Group INC | $40.68 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $32.23 | 2021-2025 | Slynd |
| Ultragenyx Pharmaceutical INC. | $20.84 | 2025 | Crysvita |
| Chiesi USA, INC. | $20.21 | 2024 | Filsuvez |
| Ars Pharmaceuticals Operations, INC. | $19.14 | 2025 | Neffy |
| Vertical Pharmaceuticals, LLC | $18.87 | 2019 | |
| Millicent US INC | $16.28 | 2025 | Femlyv |
| Kaleo, INC. | $12.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Fecko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.